Back to results
US 2019/0314308 A1Published application
Treatment of fragile x syndrome
AssigneeHealx Limited
InventorDavid Brown
Life of this patent
Estimating the term…
Abstract
Described herein is the use of sulindac in the treatment of fragile X syndrome (FXS).
Claims19
1-13. (canceled)
A method of treating fragile x syndrome comprising administering to a subject in need thereof a therapeutically effective amount of sulindac or a pharmaceutically acceptable salt thereof.
(canceled)
Dependencies are inferred from the claim text.